Edesa Biotech Research, Inc.
$14,053,500.00 CAD
- Program
- SIF Stream 1 - R&D
- Recipient country
- Canada
- Fiscal year
- 2020-2021
- Agreement period
- February 2, 2021 – December 31, 2030
- Reference
- ic:033-2020-2021-Q4-513437
Published purpose
Edesa will complete a pre-clinical study, and Phase II trials to evaluate the safety and efficacy of an antibody treatment (EB05) in hospitalized COVID-19 patients.
In plain English AI-generated
Edesa Biotech Research, Inc. received funding to conduct pre-clinical studies and Phase II trials evaluating an antibody treatment (EB05) for hospitalized COVID-19 patients.
Category: Health Primarily funds activity in Canada
Based on the published description. See how AI categorization works — the linked official record is authoritative.
Community tags
Tags are applied by readers, not by this site. One tag per person per record.